

Contents

List of Contributors	ix	Adiponectin	34
Preface	xi	Structure and Secretion of Adiponectin	34
Biographies	xiii	Adiponectin Receptors: Structure and Function	35
		Adiponectin in Obesity	37
		Adiponectin as an Insulin-Sensitizing Hormone	37
		Adiponectin and Atherosclerosis	37
		Adiponectin and Hypertension	38
		Adiponectin and Dyslipidemia	38
		Adiponectin and the Metabolic Syndrome	38
		Current and Future Therapeutic Targets	38
		References	39
1. Endothelial Biology: The Role of Circulating Endothelial Cells and Endothelial Progenitor Cells		5. Use of Stem Cells in Ischemic Heart Disease	
JOHN ARTHUR McCLUNG AND NADER G. ABRAHAM		SOHAIB TARIQ, CHHAYA AGGARWAL AND WILBERT S. ARONOW	
What Are Endothelial Progenitor Cells?	1	Introduction	43
Paracrine Effects of BM-Derived Cells	3	Mechanism of Action	44
Mechanisms, Known and Unknown	3	Stem Cell Delivery	44
Circulating Endothelial Cells and Microparticles: The Other Side of the Coin?	5	Types of Stem Cells	45
Clinical Data and Potential Applications	7	Conclusions	46
Summary and Conclusions	9	References	47
References	10		
2. The Role of Vascular Smooth Muscle Phenotype in Coronary Artery Disease		6. Vasculogenesis and Angiogenesis	
PETRA ROCIC AND SACHIN GUPTA		DHAVAL KOLTE, JOHN ARTHUR McCLUNG AND WILBERT S. ARONOW	
Introduction	15	Vasculogenesis	49
Atherosclerosis	18	Angiogenesis	51
Restenosis	19	Therapeutic Vasculogenesis/Angiogenesis for Ischemic Heart Disease	56
Arteriogenesis	20	Summary	61
Conclusions	21	References	61
References	21		
3. Immuno-Inflammatory Basis of Atherosclerotic Coronary Artery Disease		7. Lipids in Coronary Heart Disease: From Epidemiology to Therapeutics	
NAGA VENKATA POTHINENI, SOTIRIOS K. KARATHANASIS AND JAWAHAR L. MEHTA		SETH S. MARTIN, PARAG H. JOSHI AND ERIN D. MICHOS	
Inflammation and CAD—Molecular Mechanisms	23	Introduction	67
Clinical Associations of Inflammation and CAD	25	Nonpharmacologic Management of Lipids	68
Imaging the Inflammation in CAD	26	LDL-C and LDL-Targeted Therapeutics	69
Immunity and CAD	26	HDL-C and HDL-Targeted Therapeutics	71
Inflammatory Biomarkers and CAD	27	Triglycerides	74
Anti-inflammatory Therapies in CAD	28	Conclusion	76
Immune Therapies in CAD	29	References	76
Conclusions	30		
References	30	8. Genetics of Coronary Disease	
4. Adiponectin: A Mediator of Obesity, Insulin Resistance, Diabetes, and the Metabolic Syndrome		BRIAN G. KRAL AND LEWIS C. BECKER	
MALA SHARMA, JOHN ARTHUR McCLUNG AND NADER G. ABRAHAM		The GWAS Era	81
Role of Oxidative Stress and Inflammation in Obesity	33	Importance of Defining the Phenotype	88
Cytoprotective Heme Oxygenase/Adiponectin Axis	34	Significance and Replication	88

Biological and Functional Relevance	89	13. Magnetic Resonance Imaging for	
The 9p21.3 Risk Locus	90	Clinical Use and Research Investigation	
SORT1/CELSR2/PSRC1	92	in Coronary Artery Disease	
PCSK9	92	AMAR SHAH	
SH2B3	92	Introduction	153
Additional GWAS Variants Associated with CAD	93	Technique	153
Assessing Genetic Risk	93	Coronary MRA Technique	154
Future Directions	94	Field Strength	154
Summary	94	Acquisition Techniques Available for Coronary MRA	154
References	94	Coronary MRA Compared to CCTA	155
		Current Applications	155
		CCTA Compared to Coronary MRA	155
		Role of Coronary MRA in Specific Patient Populations	156
		Conclusions	157
		References	157
9. The Role of Nitric Oxide and the Regulation of Cardiac Metabolism			
ELIZABETH KERTOWIDJOJO, KHALED QANUD, SU SONG, SULLI POPILSKIS, JOHN ARTHUR McCLUNG AND THOMAS H. HINTZE			
Functional Anatomy of the Heart	103	14. Invasive Diagnostic Assessment of Coronary Artery Disease	
Role of Nitric Oxide and Reactive Dilatation in Coronary Artery Vasomotion	103	WILBERT S. ARONOW	
Organic Nitrates, Prostanoids, and Vasoconstrictors	105	Fractional Flow Reserve	159
NO as a Mediator of Pharmaceutical Agents	106	Intravascular Ultrasound	160
Conclusion	107	Optical Coherence Tomography	162
References	107	IVUS and FFR in Assessment of Left Main Disease	162
		Near Infrared Spectroscopy	163
		Conclusions	164
		References	164
10. Revascularization for Silent Myocardial Ischemia			
DHAVAL KOLTE AND JULIO A. PANZA			
Pathophysiology of Silent Myocardial Ischemia: A Historical Perspective	111	15. Drug Treatment of Stable Coronary Artery Disease	
Magnitude of the Problem	112	WILBERT S. ARONOW AND WILLIAM H. FRISHMAN	
Prognostic Significance of Silent Myocardial Ischemia	112	Risk Factor Reduction	167
Revascularization for Silent Myocardial Ischemia	115	Aspirin	168
Role of Myocardial Ischemia in Decision Making	119	Clopidogrel	169
Conclusion	120	Vorapaxar	169
References	120	Anticoagulants	169
		Beta-Adrenergic Blockers	170
		Nitrates	170
		Other Antianginal Drugs	171
		Angiotensin-Converting-Enzyme Inhibitors	171
		Aldosterone Antagonists	171
		Calcium Channel Blockers	172
		Antiarrhythmic Therapy	172
		Hormone Replacement Therapy	173
		Influenza Vaccination	174
		Depression	174
		Cardiac Rehabilitation	174
		Coronary Revascularization	174
		References	174
11. Noninvasive Diagnostic Modalities for the Evaluation of Coronary Artery Disease			
DIWAKAR JAIN AND WILBERT S. ARONOW			
Introduction	125	16. Percutaneous Coronary Intervention	
Conclusion	137	SAHIL KHERA, DHAVAL KOLTE AND DEEPAK L. BHATT	
References	137	History	179
		Indications	179
		Vascular Access	181
12. Current Approaches to Treatment of Ventricular Arrhythmias in Patients with Coronary Artery Disease			
JASON T. JACOBSON, SEI IWAI AND WILBERT ARONOW			
Introduction	141		
VAs in the Setting of Acute Ischemia and Infarction	141		
VAs in the Setting of ICM	142		
Medical Therapy	143		
Implantable Cardiac Defibrillator	144		
Conclusions	149		
References	149		

		CONTENTS	vii
Intracoronary Devices	182	Indications	210
Antiplatelet Agents	184	Technical Considerations	210
Anticoagulants	186	Management Considerations	210
Complications of PCI	187	Clinical Outcomes	212
Controversies and Future Directions	188	Ethics	212
Conclusions	190	Economics	213
References	190	Conclusions	213
		References	213
17. Current Topics in Bypass Surgery			
MICHAEL E. HALKOS		19. Biostatistics Used for Clinical	
		Investigation of Coronary Artery Disease	
Introduction	195	CHUL AHN	
CABG versus PCI	195		
Multiarterial Grafting	198	Introduction	215
Off-Pump versus On-Pump CABG	200	Observational Study	215
Postoperative Stroke	200	Experimental Study	219
Minimally Invasive CABG and HCR	202	Discussion	220
Disclosures	205	References	220
References	205		
		Index	223
18. Peripheral Veno-arterial Extracorporeal			
Membrane Oxygenation for Treatment			
of Ischemic Shock			
STEVE K. SINGH, DAVID SPIELVOGEL, STEVEN L. LANSMAN			
AND GILBERT H.L. TANG			
Introduction	209		
Evolution to Contemporary ECMO	209		